DelistingMay 5, 2026, 04:08 PM
MUSTANG BIO Faces Nasdaq Delisting Threat; Q1 Net Loss $0.96M
AI Summary
Mustang Bio, a clinical-stage biopharmaceutical company, received a Nasdaq delisting notice on April 15, 2026, for failing to meet the minimum bid price requirement. The company has until October 12, 2026, to regain compliance. For the first quarter of 2026, Mustang Bio reported a net loss of $0.96 million, an increase from $0.15 million in the prior year, with cash and cash equivalents at $16.3 million. The company continues to incur substantial operating losses and does not expect product sales revenue in the foreseeable future.
Key Highlights
- Received Nasdaq delisting notice on April 15, 2026, for minimum bid price non-compliance.
- Has 180-day grace period until October 12, 2026, to regain Nasdaq compliance.
- Q1 2026 net loss increased to $0.96 million from $0.15 million in Q1 2025.
- Cash and cash equivalents stood at $16.3 million as of March 31, 2026.
- Accumulated deficit reached $399.6 million as of March 31, 2026.
- Total operating expenses for Q1 2026 were $1.06 million, up from $0.25 million in Q1 2025.
- Issued 278,385 common shares to Fortress as Annual Stock Dividend on January 1, 2026.
- Approximately $34.2 million remains available under the 2024 S-3 shelf registration statement.
Price Impact
More from MBIO